A novel mifepristone-loaded implant for long-term treatment of endometriosis: In vitro and in vivo studies

European Journal of Pharmaceutical Sciences

Volumn 39, Issue 5, 2010, Pages 421-427

  Mei, Lin ^a,b,c,d   Bao, Junbo ^a   Tang, Lina ^a   Zhang, Chao ^a   Wang, Hai ^a   Sun, Leilei ^b   Ma, Guilei ^a   Huang, Laiqiang ^c,d   Yang, Jing ^a   Zhang, Linhua ^a   Liu, Kexin ^b   Song, Cunxian ^a   Sun, Hongfan ^a  

^a INSTITUTE OF BIOMEDICAL ENGINEERING   (China)

^b DALIAN MEDICAL UNIVERSITY   (China)

^c TSINGHUA UNIVERSITY   (China)

^d Center for Biotech and Bio Medicine   (China)

Author keywords

Endometriosis; Implant; Long term treatment; Mifepristone; Polycaprolactone Pluronic F68

Indexed keywords

MIFEPRISTONE; POLOXAMER;

ADENOMYOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; DISPERSION; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG IMPLANT; DRUG RELEASE; DRUG SOLUBILITY; ENDOMETRIOSIS; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LONG TERM CARE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURFACE PROPERTY; SUSTAINED DRUG RELEASE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG IMPLANTS; ENDOMETRIOSIS; FEMALE; HORMONE ANTAGONISTS; MICROSCOPY, ELECTRON, SCANNING; MIFEPRISTONE; MOLECULAR WEIGHT; RATS; RATS, WISTAR; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

EID: 77649188555     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2010.01.012     Document Type: Article

References (31)

1. David L.O., and Elizabeth A.P. Treatment of endometriosis. N. Engl. J. Med. 345 (2001) 266-275
2. Farquhar C., and Sutton C. The evidence for the management of endometriosis. Curr. Opin. Obstet. Gynecol. 10 (1998) 321-332
3. Fedele L., and Berlanda N. Emerging drugs for endometriosis. Expert Opin. Emerg. Drugs 9 1 (2004) 167-177
4. Heikinheimo O., and Kekkonen R. Dose-response relationship of RU 486. Ann. Med. 25 (1993) 71-76
5. Heikinheimo O., Lähteemäki P.L., Koivunen E., Shoupe H., Croxatto D., Luukkainen T., et al. Metabolism and serum binding of RU 486 in women after various single doses. Hum. Reprod. 2 (1987) 379-385
6. Hiljanen-vainio M., Karjalainen T., and Seppala J. Biodegradable lactone copolymers. 1. Characterization and mechanical behavior of ε-caprolactone and lactide copolymers. J. Appl. Polym. Sci. 59 (1996) 1281-1288
7. Ho P.C., Ng E.H.Y., and Tang O.S. Mifepristone: contraceptive and non-contraceptive uses. Curr. Opin. Obstet. Gynecol. 14 (2002) 325-330
8. Hutmacher D.W. Scaffolds in tissue engineering bone and cartilage. Biomaterials 21 24 (2000) 2529-2543
9. Jones R.C. The effect of a luteinizing hormone releasing hormone (LRH) agonist (Wy240,972), levonorgestrel danazol and ovariectomy on experimental endometriosis in the rat. Acta Endocrinol. 106 2 (1984) 282-284
10. Kauppila A. Changing concepts of medical treatment of endometriosis. Acta Obstet. Gynecol. Scand. 72 (1993) 324-336
11. Kekkonen R., Heikinheimo O., Mandelin E., and Lähteemäki P. Pharmacokinetics of mifepristone after low oral doses. Contraception 54 (1996) 229-234
12. Kettel L.M., Murphy A.A., Mortola J.F., Liu J.H., Ulmann A., and Yen S.S.C. Endocrine responses to long-term administration of the antiprogesterone RU486 in patient with pelvic endometriosis. Fertil. Steril. 56 (1991) 402-407
13. Kettel L.M., Murphy A.A., Morales A.J., Ulmann A., Baulieu E.E., and Yen S.S.C. Treatment of endometriosis with the antiprogesterone mifepristone (RU486). Fertil. Steril. 65 (1996) 23-28
14. Kettel L.M., Murphy A.A., Morales A.J., and Yen S.S. Preliminary report on the treatment of endometriosis with low dose mifepristone (RU 486). Am. J. Obstet. Gynecol. 178 (1998) 1151-1156
15. Li S., and Vert M. Biodegradable polymers: polyesters. In: Mathiowitz E. (Ed). Encyclopedia of Controlled Drug Delivery (1999), Wiley, New York 71-93
16. Ma G., Song C., Sun H., Yang J., and Leng X. A biodegradable levonorgestrel-releasing implant made of PCL/F68 compound tested in rats and dogs. Contraception 74 2 (2006) 141-147
17. Mei L., Sun H., and Song C. Local delivery of modified paclitaxel-loaded poly (epsilon-caprolactone)/pluronic F68 nanoparticles for long-term inhibition of hyperplasia. J. Pharm. Sci. 98 6 (2009) 2040-2050
18. Pitt C.G. Poly (ε-caprolactone) and its copolymers. In: Chasin M., and Langer R. (Eds). Biodegradable Polymers as Drug Delivery Systems (1990), Marcel Dekker, New York 71-120
19. Pitt C.G., Margit M.M., Jeffcoat A.R., Zweidinger R., and Schindler A. Sustained drug delivery systems. II. Factors affecting release rates from poly (ε-caprolactone) and related biodegradable polyesters. J. Pharm. Sci. 68 (1979) 1534-1538
20. Pitt C.G., Chasalw F.L., and Schindler A. Aliphatic polyester. 1. The degradation of poly (ε-caprolactone) in vivo. J. Appl. Polym. Sci. 26 (1981) 3779-3787
21. Shah T.J., Amin A.F., Parikh J.R., and Parikh R.H. Process optimization and characterization of poloxamer solid dispersions of a poorly water-soluble drug. AAPS PharmSciTech. 13 2 (2007) Article 29, 8
22. Shi Y.E., Ye Z.Y., and He C.H. Pharmacokinetic study of RU486 and its metabolites after oral administration of single doses to pregnant and nonpregnant women. Contraception 48 (1993) 133-149
23. Song C.X., Labhasetwar V., and Levy R.J. Controlled release of U-86983 from double-layer biodegradable matrices: effect of additives on release mechanism and kinetics. J. Control. Release 45 (1997) 177-192
24. Stith C., and Hussain M.D. Determination of mifepristone levels in wild canid serum using liquid chromatography. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 794 (2003) 9-15
25. Sun H., Mei L., Song C., Cui X., and Wang P. The in vivo degradation, absorption and excretion of PCL-based implant. Biomaterials 27 (2006) 1735-1740
26. Tang O.S., and Ho P.C. Clinical applications of mifepristone. Gynecol. Endocrinol. 22 12 (2006) 655-659
27. Telimaa S., Apter D., Reinilä M., Rönnberg L., and Kauppila A. Placebo-controlled comparison of hormonal and biochemical effects of danazol and high-dose medroxyprogesterone acetate. Eur. J. Obstet. Gynecol. Reprod. Biol. 36 (1990) 97-105
28. Vercellini P., Cortesi I., and Crosignani P.G. Progestins for symptomatic endometriosis: a critical analysis of the evidence. Fertil. Steril. 68 (1997) 393-401
29. In: Wade A., and Weller P.J. (Eds). Handbook of Pharmaceutical Excipients. 2nd ed. (1994), American Pharmaceutical Association, Washington, DC 352-354
30. Waller K.G., and Shaw R.W. Gonadotropin-releasing hormone analogues for the treatment of endometriosis: long-term follow-up. Fertil. Steril. 59 (1993) 511-515
31. Yan F., Zhang C., Mei L., Zheng Y., Song C., Sun H., et al. The effect of poloxamer 188 on nanoparticle morphology, size, cancer cell uptake, and cytotoxicity. Nanomed. Nanotechnol. Biol. Med. 6 1 (2010) e170-e178